CNTB: Xanthopoulos Kleanthis Gabriel discloses securities transactions

By AlphaYouPublished Oct 1, 2026Form 4

Stocks in this disclosure

Reported activity

Xanthopoulos Kleanthis Gabriel

Reporting filer

Xanthopoulos Kleanthis Gabriel reported Grant or award in Connect Biopharma Holdings Ltd: 5000 units of Ordinary Shares, dated 2026-09-30. The full Form 4 contains 1 transaction entry.

Disclosed: Oct 1, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Ordinary Shares	Xanthopoulos Kleanthis Gabriel	2026-09-30	A	Grant or award	5000	0	91,554	1 day	Filed terms security Title: Ordinary Shares transaction Date: 2026-09-30 transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 transaction Shares: 5000 id: F1 transaction Price Per Share: 0 transaction Acquired Disposed Code: A shares Owned Following Transaction: 91554 direct Or Indirect Ownership: D

Ordinary Shares

Owner: Xanthopoulos Kleanthis Gabriel
Date: 2026-09-30
Code: A
Action: Grant or award
Quantity: 5000
Price: 0
Following holdings: 91,554
Reporting delay: 1 day
Filed terms and references: Filed terms
security Title: Ordinary Shares
transaction Date: 2026-09-30
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Shares: 5000
id: F1
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 91554
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Xanthopoulos Kleanthis Gabriel: Director.
F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Ordinary Shares

Xanthopoulos Kleanthis Gabriel

2026-09-30

Grant or award

5000

91,554

1 day

Filed terms

security Title: Ordinary Shares
transaction Date: 2026-09-30
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Shares: 5000
id: F1
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
shares Owned Following Transaction: 91554
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

Xanthopoulos Kleanthis Gabriel: Director.

F1: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.